The in vitro susceptibilities of 86 recent clinical isolates of Brucella melitensis to minocycline, streptomycin, co-trimoxazole, rifampin, and six fluoroquinolones were determined. Minocycline exhibited the lowest MIC and was followed by rifampin and streptomycin. Among the quinolones, WIN 57273 and ciprofloxacin were the most active agents. No antibiotic combination of these agents exhibited synergy against 15 selected isolates. In killing rate experiments, streptomycin exhibited the most rapid kill (<12 h), while a complete kill with minocycline, rifampin, and ciprofloxacin was delayed up to 48 h. The combinations of streptomycin with each of minocycline, rifampin, or ciprofloxacin exhibited the fastest kills (within 2 h), while with the other combinations, a complete kill was delayed up to 96 h. These results demonstrate the discrepancy between the results of various in vitro methods in evaluating the antibiotic susceptibility of B. melitensis.
Human brucellosis is an important ongoing medical problem. The Mediterranean basin is one of the most heavily afflicted regions (7) . Despite the availability of many antibacterial agents, the complete cure of the infection with prevention of the frequent relapses is still an unattainable goal (7) . The new fluoroquinolone antibacterial agents, because of their broad spectrum of bactericidal activity against a variety of gram-negative bacteria and because of their favorable intracellular penetration, could potentially be candidates for the therapy of brucellosis (13, 19) . We therefore tested the in vitro activities of several fluoroquinolones (pefloxacin, ofloxacin, ciprofloxacin, fleroxacin, sparfloxacin, and WIN 57273) and compared them with the activities of the conventional anti-Brucella antibiotics: tetracycline, streptomycin, rifampin, and sulfamethoxazole-trimethoprim (co-trimoxazole), recommended for the therapy of brucellosis. In addition, we also studied the possible synergistic effects of several combinations of these antibiotics.
Bacteria. Eighty-six Brucella melitensis strains isolated from patients at three different geographical districts in Israel were used. The identities of all B. melitensis strains were confirmed (by Menachem Banai) in the National Brucella Reference Laboratory by the Stamp stain appropriate biochemical reactions and by phage typing (2) . Stock strains were kept frozen in small aliquots at -80°C and were kept between experiments on agar slants.
Antibiotics. Antibiotics were obtained from their manufacturers as laboratory powders and were reconstituted in their recommended diluents to yield stock solutions of 1,000 ,u.g/ml that were kept at -70°C. Minocycline (Lederle, Pearl River, N.Y.) was used as a representative of the tetracycline family. Streptomycin sulfate (Teva, Jerusalem, Israel), sulfamethoxazole-trimethoprim (Wellcome, Beckenham, United Kingdom), rifampin (Ciba-Geigy, Basel, Switzerland), ciprofloxacin (Bayer AG, Leverkusen, Germany), ofloxacin (Hoechst AG, Frankfurt, Germany), pefloxacin and sparfloxacin (Rhone-Poulenc-Rorer, Antony, France), and WIN 57273 (Parke-Davis, Pharmaceutical Research Division, Warner-Lambert Co., Ann Arbor, Mich.) were tested as well. * Corresponding author.
Susceptibility testing. The well broth microdilution method was used with 96-well plates, (Nunc, Roskilde, Denmark) (14) . Antibiotics were diluted twofold in Brucella broth (Difco, Detroit, Mich.) and wells were inoculated with 105 CFU of bacteria (in a 0.2-ml final volume). The incubation period was 48 h in 5% CO2 at 37°C. The lowest concentration that completely inhibited visual growth was recorded and interpreted as the MIC. All tests were performed in triplicate and then averaged. In addition, all MICs were determined by the agar dilution method by using Brucella agar (Difco) containing graded concentrations of antibiotics and inocula of 104 to 105 cells per spot, applied with a replica plating (14) instrument. Plates were also incubated under 5% CO2 for 48 h at 37°C.
Antibiotic combinations. Fifteen Brucella strains were picked at random for this study. Combination studies were initially performed with the agar plate dilution method as described previously, except that the plates contained antibiotic concentrations in double dilutions of each of the two antibiotic agents tested; therefore, for each combination determination, 56 plates were used. Strains that showed synergy, or a marked additive effect, or antagonism were retested by the broth dilution method, with each tube containing the final antibiotic concentration used in the agar plates. In this checkerboard test, synergy was defined as a fractional inhibitory concentration index (e) of .0.5. Antagonism was defined as E-1, and indifference was defined as 0.5 ' E s 1.
Determination of killing rates. B. melitensis no. 40 (picked at random) was used, and the killing rate was determined with an initial inoculum of 105 CFU/ml in tubes containing Brucella broth. The investigated antibiotics were tested at concentrations of 4x the respective MIC either as single agents or in the following five combinations: streptomycin and rifampicin, streptomycin and ciprofloxacin, streptomycin and minocycline, ciprofloxacin and rifampin, and minocycline and rifampin. A tube containing no antibiotics was also employed. Tubes were incubated in the conditions mentioned above. Aliquots were obtained at the following times: 0 min, 30 min, 2 h, 8 h, 12 accurately detectable number of CFU per milliliter was 10. This number was determined in previous tests by using various bacterial dilutions in this broth following the incubation conditions mentioned above. Susceptibility studies. Minocycline was the most active antibiotic in vitro against B. melitensis, showing the lowest MIC among the conventional anti-Brucella agents. It was ca. 10-fold more active (on a per-weight basis) than the next most active antibiotics, rifampin and streptomycin. Cotrimoxazole was the least active drug (Table 1) . Among the fluoroquinolones, WIN 57273 and ciprofloxacin were the most active agents, followed by sparfloxacin, ofloxacin, and pefioxacin. Fleroxacin was the least active agent (on the basis of weight); however, the differences in MICs were rather small (Table 1) . Of the 15 Brucella strains chosen for the antibiotic combination studies, no combination exhibited synergy against any of the strains (data not shown).
Killing studies. Brucella control isolates grew slowly, increasing from 3 x 105 to 1 x 106 CFU/ml at 24 h to 7.4 x 106 CFU/ml at 48 h and to 8.3 x 109 CFU/ml at 96 h ( Table   2 ). Streptomycin alone caused complete killing by 12 h at 4x the MIC (Table 2 ) and was the fastest acting agent. Minocycline, rifampin, and ciprofloxacin each caused delayed kills, at 24 h. The original inoculum decreased by no more than 1.5 log; however, complete kills occurred between 24 and 48 h.
The combinations of streptomycin and rifampin, streptomycin and minocycline, and streptomycin and ciprofloxacin (Table 3 ) exhibited the fastest kills at 4x the MIC; after 2 h of exposure, no viable organisms were detected. The combinations of minocycline and rifampin and ciprofloxacin and rifampin (Table 3) caused bacterial killing only at 24 h. The combination of minocycline and ciprofloxacin was the least potent drug combination, causing bacterial killing only at 96 h. A recent epidemic of brucellosis in Israel drew our attention to the frequent clinical relapses that occurred following the discontinuation of ciprofioxacin treatment, an observation that has also been made with other quinolones, in both this and other countries (5, 16) . This observation stands in contrast to the relatively low MICs for B. melitensis both as determined in the present investigation and as reported previously (1, 5, 6, 15, 18) . We therefore determined the in vitro susceptibility of recent B. melitensis clinical isolates to various antibiotics and their combinations and also measured the killing effect of these antibiotics.
Minocycline demonstrated the lowest MIC in our study, a finding that has been repeatedly demonstrated for the various tetracycline compounds (8, 10, 11) . The low MIC, however, was not accompanied by a rapid kill. WIN 57273, a fluoroquinolone that is still in the experimental stage, had the next lowest MIC, and ciprofloxacin and sparfloxacin followed with MICs for 50% of the strains tested (MIC50s) of 0.4 and 0.8 ,ug/ml, respectively, and MIC90s of 0.8 and 1.5 ,g/ml, respectively. These MICs are similar to those reported previously (1, 5, 6, 15, 18) . Streptomycin, co-trimoxazole, and rifampin demonstrated somewhat higher MICs (Table 1) ; however, their MIC90s were similar to their MIC50s, representing a limited susceptibility distribution pattern. The MIC of streptomycin remained essentially unchanged from that observed by many investigators for the past half century (3, 12) . Rifampin MIC90s in previous studies were reported to range from 0.02 to 0.10 ,ug/ml, values confirmed again by our findings (8, 10, 12) . In vitro susceptibility to co-trimoxazole was also found to be in the range described previously. Despite its adequate in vitro susceptibility, the high clinical failure rate observed with this agent in the therapy of brucellosis in controlled clinical studies has eliminated its use for this infection (4, 10) . This curious asymmetry between in vitro test results and clinical results has also been observed with some quinolones (16, 18) and may be explained by the recent observation that the quinolones exert merely a bacteriostatic effect against Brucella strains (9) .
For pefloxacin, fleroxacin, and ofloxacin, the differences between the MIC50s and the MIC90s were larger than for the conventional antibiotics ( Synergy, as determined by killing rates of the test organism, demonstrated that the combinations of streptomycin and minocycline, ciprofloxacin, or rifampin resulted in rapid killing (<2 h), while the slowest killing rate was observed for the combination of ciprofloxacin and minocycline, a killing rate that was slower than for each of constituents of the combination, suggesting a possible antagonism. These in vitro results are in accordance with previous clinical results (4, 7) and with our as yet unpublished animal experiments.
Cisneros et al. (7) recently reported a high success rate for the treatment of human brucellosis with the combination of doxycycline and streptomycin, a combination that in our in vitro study also demonstrated the most rapid bactericidal activity. In accordance with our in vitro results, the combination of tetracycline and rifampin resulted in a ca. 53% relapse rate (4), far above the rate reported for doxycycline and streptomycin.
The use of the quinolones in combination with other antibiotics has not yet been tested. Our results suggest the combination of a quinolone with tetracycline should be discouraged, while the combination of quinolone with streptomycin may be more efficacious. Considering the fact that Brucella spp. are intracellular pathogens, the MIC determinations and killing studies not performed in tissue culture may not reflect the actual in vivo process. Unfortunately, however, even the use of animal experiments failed to predict clinical results, at least for rifampin and tetracycline (17) .
